Lyme disease is the most common tick-borne infection in both
North America and Europe. In the United States, Lyme disease is caused by
Borrelia burgdorferi, which is transmitted by the bite of the tick species
Ixodes scapularis and Ixodes pacificus. Clinical manifestations most often
involve the skin, joints, nervous system, and heart. Link to full
Approximately every 12 – 18 months following
publication, IDSA evaluates its guidelines for the need for update. Because
several years have passed since the last update, IDSA determined that a new
undertaking for Lyme disease guidelines was needed.
In order to develop
a more focused and manageable guideline than the previous guideline which had a
very broad scope, the IDSA has decided to approach this guideline topic
differently by separating the topic into distinct guidelines. This is a
practice that IDSA has implemented across many of its guidelines where the
scope has been expansive.
The first of these guideline topics to be
addressed will be on the prevention, diagnosis, and treatment of Lyme disease.
This guideline is being developed jointly with the American Academy of
Neurology and the American College of Rheumatology. Other collaborators on the
guideline include panel members from the following: American Academy of Family
Physicians (AAFP), American Academy of Pediatrics – Committee on Infectious
Diseases (AAP-COID), American Academy of Pediatrics – Section on Emergency
Medicine (AAP-EM), American College of Physicians (ACP), Association of Medical
Microbiology and Infectious Diseases – Canada (AMMI-CA), Child Neurology
Society (CNS), Pediatric Infectious Diseases Society (PIDS), Entomological
Society of America (ESA), European Society of Clinical Microbiology and
Infectious Diseases (ESCMID). Individuals from the disciplines of cardiology,
microbiology and pathology as well as a consumer representative and a
methodologist with expertise in GRADE are also among the members of the
guideline development panel.
In contrast to the 2006 IDSA
guidelines, this guideline will not provide comprehensive coverage of Anaplasma
phagocytophilum and Babesia microti outside the context of coinfections. Those
pathogens will be treated more comprehensively in separate, forthcoming
A Project Plan has been developed for the
prevention, diagnosis, and treatment of Lyme disease and is available from
March 9 to April 9 for a 30 day Public Comment period. Additional information
can be found here.
Information on the status of these updates can be found here,
within the Practice Guidelines/Infections by Organism/Bacteria section of the